Biomea Fusion, Inc. Increase (Decrease) in Other Operating Assets
Biomea Fusion, Inc. (BMEA) reported Increase (Decrease) in Other Operating Assets of $398.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-05
- Biomea Fusion, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was -$4.00K.
- Biomea Fusion, Inc. increase (decrease) in other operating assets for the quarter ending 2025-06-30 was -$613.00K, a 7762.50% decline year-over-year.
- Biomea Fusion, Inc. increase (decrease) in other operating assets for the quarter ending 2025-03-31 was -$2.00K, a 100.16% decline year-over-year.
- Biomea Fusion, Inc. increase (decrease) in other operating assets for the quarter ending 2024-12-31 was -$4.01M, a 694.96% decline year-over-year.
- Biomea Fusion, Inc. increase (decrease) in other operating assets for fiscal 2024 was -$4.88M, a 307.12% decline from fiscal 2023.
- Biomea Fusion, Inc. increase (decrease) in other operating assets for fiscal 2023 was $2.36M, a 23.13% increase from fiscal 2022.
- Biomea Fusion, Inc. increase (decrease) in other operating assets for fiscal 2022 was $1.92M, a 57.22% increase from fiscal 2021.
- Biomea Fusion, Inc. increase (decrease) in other operating assets for fiscal 2021 was $1.22M, a 10050.00% increase from fiscal 2020.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $398.00K 10-Q · filed 2026-08-05 | |||
| 2025-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$617.00K derived: sum of 2 quarters · filed 2026-08-05 | -$619.00K 10-Q · filed 2025-11-04 | -$4.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$613.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$615.00K 10-Q · filed 2026-08-05 | -$4.63M derived: sum of 3 quarters · filed 2026-08-05 | -$6.74M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$2.00K 10-Q · filed 2026-05-11 | -$4.01M derived: sum of 2 quarters · filed 2026-05-11 | -$6.13M derived: sum of 3 quarters · filed 2026-05-11 | -$6.12M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$6.13M derived: sum of 2 quarters · filed 2025-11-04 | -$6.12M derived: sum of 3 quarters · filed 2025-11-04 | -$4.88M 10-K · filed 2025-03-31 |
| 2024-09-30 | -$2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.11M derived: sum of 2 quarters · filed 2025-11-04 | -$874.00K 10-Q · filed 2025-11-04 | -$200.00K derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.24M 10-Q · filed 2025-08-05 | $1.92M derived: sum of 3 quarters · filed 2025-08-05 | $2.84M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $1.24M 10-Q · filed 2025-05-05 | $1.91M derived: sum of 2 quarters · filed 2025-05-05 | $2.83M derived: sum of 3 quarters · filed 2025-05-05 | $2.85M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $674.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.60M derived: sum of 2 quarters · filed 2025-03-31 | $1.61M derived: sum of 3 quarters · filed 2025-03-31 | $2.36M 10-K · filed 2025-03-31 |
| 2023-09-30 | $923.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $940.00K derived: sum of 2 quarters · filed 2024-10-29 | $1.68M 10-Q · filed 2024-10-29 | $4.35M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $761.00K 10-Q · filed 2024-07-31 | $3.42M derived: sum of 3 quarters · filed 2025-03-31 | $2.28M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | $744.00K 10-Q · filed 2024-05-02 | $3.41M derived: sum of 2 quarters · filed 2025-03-31 | $2.27M derived: sum of 3 quarters · filed 2025-03-31 | $2.29M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.52M derived: sum of 2 quarters · filed 2025-03-31 | $1.55M derived: sum of 3 quarters · filed 2025-03-31 | $1.92M 10-K · filed 2025-03-31 |
| 2022-09-30 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | -$1.12M derived: sum of 2 quarters · filed 2023-10-30 | -$747.00K 10-Q · filed 2023-10-30 | $460.00K derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $394.00K 10-Q · filed 2023-07-31 | $1.60M derived: sum of 3 quarters · filed 2024-03-28 | $1.62M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $369.00K 10-Q · filed 2023-05-02 | $1.58M derived: sum of 2 quarters · filed 2024-03-28 | $1.60M derived: sum of 3 quarters · filed 2024-03-28 | $1.60M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.23M derived: sum of 2 quarters · filed 2024-03-28 | $1.23M derived: sum of 3 quarters · filed 2024-03-28 | $1.22M 10-K · filed 2024-03-28 |
| 2021-09-30 | $23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $23.00K derived: sum of 2 quarters · filed 2022-11-07 | $11.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | -$12.00K 10-Q · filed 2022-08-01 | ||
| 2021-03-31 | -$12.00K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $12.00K 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |